Kartos Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor. Launched in 2018 by proven industry veterans, we are a passionate team based in Redwood City, California, and Bellevue, Washington. We have brought together scientists and clinicians with a deep understanding of hematology and oncology and an experienced leadership team. Together, we’re building an exciting biotechnology company with a culture defined by caring, ambition, dedication, and teamwork!
Company Details
- Employees
- 68
- Founded
- -
- Address
- 275 Shoreline Dr,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- kartosthera.com
- HQ
- Redwood City, California
Kartos Therapeutics, Inc. Questions
Kartos Therapeutics, Inc.'s website is kartosthera.com
Kartos Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/kartos-therapeutics
Kartos Therapeutics, Inc. has
68 employees.
View email and phone details for 68
employees at Kartos Therapeutics, Inc..
Kartos Therapeutics, Inc.'s industry is
Biotechnology Research
Kartos Therapeutics, Inc.'s top competitors are
Bridgebio,
Vera Therapeutics, Inc.,
Candid Therapeutics,
Pulse Biosciences, Inc.,
Bicara Therapeutics,
Summit Therapeutics, Inc.,
Corcept Therapeutics,
Telios Pharma, Inc.,
Viridian Therapeutics, Inc.,
Biomea Fusion.
Kartos Therapeutics, Inc.'s categories are Biotechnology Research
Kartos Therapeutics, Inc.'s founding year is 2018
